9:25 am Chairperson’s Opening Remarks
Improving Potency & Efficacy Through Design of Your ADC
9:30 am Strategies to Maximize the Effectiveness of Belantamab Mafodotin
Synopsis
- Leveraging antibody effector functions in combination with cytotoxic payloads
- Discussing manipulation of cell surface levels of target to maximize potency
- Examining the effect of DAR on efficacy
10:00 am Design Considerations for an Immunology Antibody Drug Conjugate (iADC)
Synopsis
- Outlining identification of the antibody target and parameters for selection and parameters of the optimal antibody
- Discussing considerations when choosing the payload MoA pairing for the antibody target
- Modifying of the ADC to both maximize the therapeutic index and afford the optimal physiochemical properties
10:30 am
Morning Break & Networking
Analyzing Approaches to Limit On-Target / Off-Tumor Toxicities
11:00 am A Critical Appraisal of Target Mediated & On-Target/Off-Tumor Toxicities of ADCs
Synopsis
- Understanding the critical importance of target expression and biology in maximizing the therapeutic index
- Discussing the challenges of predicting on target toxicities based on target expression on normal tissues
- Outlining the importance of the antibody quality, payload potency, linker and conjugation on target medicated toxicities
11:30 am Designing Site-Specific ADCs to Maximize Target-Mediated Payload Delivery
Synopsis
- Outlining HT identification of bioconjugation site from ADC libraries
- Discovering glycosylated variants amenable to bTGase conjugation
- Discussing characterization of thermal and metabolic stabilities of site-specific ADCs to guide construct design for maximizing target-dependent delivery
12:00 pm pHLAs as Novel Targets & Therapeutic Index Guided ADC Development
Synopsis
- pHLAs: an emerging class of ADC targets
- Therapeutic Index based stage gate decisions to guide ADC development
- Immunogenic cell death of payloads to increase DOR and PFS of ADCs
12:30 pm
Lunch & Networking
Harnessing Bioinformatics for Improved Target Selection
1:30 pm Quantitative Proteomics Approaches for ADC Target Characterization
Synopsis
- Discussing DIA-MS peptide level quantification for epitope and isoform precision
- Explore how to quantify cell surface protein dynamics using pulsed SILAC labeling
- Examine the profiling of protein drug interactions (PDIs) Using IP-MS
2:00 pm A Novel B7H3 ADC With Strong Bystander Effect Demonstrates Superior Tumor-Inhibition Activity
Synopsis
- Outlining B7H3 as a target and our novel ADC technique
- Discussing in vitro characterization and in vivo anti-tumor activity of BAT8009
- Reviewing Preclinical PK and GLP toxicity study and clinical plan/progress